Adjuvant and Neoadjuvant Radiation Therapy for Locally Advanced Bladder Cancer

B. C. Baumann, M. S. Zaghloul, P. Sargos, V. Murthy

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Local-regional failure for patients with ≥pT3 urothelial carcinoma after radical cystectomy is a significant clinical challenge. Prospective randomised trials have failed to show that chemotherapy reduces the risk of local-regional recurrences. Salvage treatment for local failures is difficult and often unsuccessful. There is promising evidence, particularly from a recent Egyptian National Cancer Institute trial, that radiation therapy plus chemotherapy can significantly reduce local recurrences compared with chemotherapy alone, and that this improvement in local-regional control may translate to meaningful improvements in disease-free and overall survival with acceptable toxicity. In light of the high rates of local failure following cystectomy for locally advanced disease and the progress that has been made in identifying patients at high risk of failure and the patterns of failure in the pelvis, the National Comprehensive Cancer Network guidelines were revised to include postoperative radiotherapy as an option to consider for patients with ≥pT3 disease. Here we review the problem of local-regional failure after cystectomy, identify patients who would probably benefit from adjuvant radiotherapy, review the patterns of pelvic failure after cystectomy, discuss technical details of radiation treatment and review the modern literature on this topic. Adjuvant radiotherapy should be considered as a treatment option for patients with locally advanced disease, especially those with positive margins or squamous cell carcinoma.

Original languageEnglish
Pages (from-to)391-399
Number of pages9
JournalClinical Oncology
Issue number6
StatePublished - Jun 2021


  • Adjuvant radiation
  • bladder cancer
  • preoperative radiation
  • radical cystectomy


Dive into the research topics of 'Adjuvant and Neoadjuvant Radiation Therapy for Locally Advanced Bladder Cancer'. Together they form a unique fingerprint.

Cite this